Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.69 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.69 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.69 |
| ▸ | LMNA | P02545 | 6/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.65 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.62 |
| ▸ | HPGD | P15428 | 1/20 | 0.62 |
| ▸ | ATM | Q13315 | 1/20 | 0.62 |
| ▸ | CA2 | P00918 | 3/20 | 0.60 |
| ▸ | CA1 | P00915 | 2/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | CA12 | O43570 | 1/20 | 0.60 |
| ▸ | CA4 | P22748 | 1/20 | 0.60 |
| ▸ | CA6 | P23280 | 1/20 | 0.60 |
| ▸ | CA5A | P35218 | 1/20 | 0.60 |
| ▸ | CA7 | P43166 | 1/20 | 0.60 |
| ▸ | CA9 | Q16790 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13685933 | 0.86 | TDP1 (0.70) | TDP1ALDH1A1CYP1A2L3MBTL1LMNA | |
| SCHEMBL13685945 | 0.85 | TDP1 (0.79) | TDP1ALDH1A1CYP1A2L3MBTL1LMNA | |
| SCHEMBL9810161 | 0.85 | TDP1 (0.71) | TDP1ALDH1A1CYP1A2L3MBTL1LMNA | |
| Ethiazide SCHEMBL30561875 | 0.84 | TDP1 (1.00) | TDP1ALDH1A1CYP1A2L3MBTL1LMNA | |
| SCHEMBL11038368 | 0.84 | TDP1 (0.77) | TDP1ALDH1A1CYP1A2L3MBTL1LMNA | |
| Ethiazide SCHEMBL122238 | 0.84 | TDP1 (1.00) | TDP1ALDH1A1CYP1A2L3MBTL1LMNA | |
| SCHEMBL29925887 | 0.82 | TDP1 (0.82) | TDP1ALDH1A1CYP1A2L3MBTL1LMNA | |
| Benzylhydrochlorothiazide SCHEMBL49671 | 0.81 | ALDH1A1 (1.00) | TDP1ALDH1A1CYP1A2L3MBTL1LMNA | |
| Benzylhydrochlorothiazide SCHEMBL18314134 | 0.81 | ALDH1A1 (1.00) | TDP1ALDH1A1CYP1A2L3MBTL1LMNA | |
| SCHEMBL13685906 | 0.81 | TDP1 (0.69) | TDP1ALDH1A1CYP1A2L3MBTL1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7595313-B2 | Nitric oxide donating diuretic compounds, compositions and methods of use | NICOX, S.A. (FR) | 2009-09-29 | — | — | US | disclosed |
| US-7595313-B2 | Nitric oxide donating diuretic compounds, compositions and methods of use | NICOX, S.A. (FR) | 2009-09-29 | — | — | US | disclosed |
| US-20080255101-A1 | NITRIC OXIDE DONATING DIURETIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2008-10-16 | — | — | US | disclosed |
| US-20080255101-A1 | NITRIC OXIDE DONATING DIURETIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2008-10-16 | — | — | US | disclosed |
| US-7396829-B2 | such as 2H-1,2,4-benzothiadiazine-7-sulfonamide, 6-chloro-3,4-dihydro-3-[5-(nitrooxy)pentyl]-, 1,1-dioxide; contains at least one nitric oxide enhancing group; excessive water or electrolyte retention conditions; cardiovascular diseases, and diseases resulting from oxidative or endothelial dysfunctions | NITROMED, INC. (US) | 2008-07-08 | — | — | US | disclosed |
| US-7396829-B2 | such as 2H-1,2,4-benzothiadiazine-7-sulfonamide, 6-chloro-3,4-dihydro-3-[5-(nitrooxy)pentyl]-, 1,1-dioxide; contains at least one nitric oxide enhancing group; excessive water or electrolyte retention conditions; cardiovascular diseases, and diseases resulting from oxidative or endothelial dysfunctions | NITROMED, INC. (US) | 2008-07-08 | — | — | US | disclosed |
| US-5017567-A | Steroid antiinflammatory | SCHERING CORPORATION (US) | 1991-05-21 | — | — | US | disclosed |
| US-4906635-A | Carboxyalkyl dipeptides as antiglaucoma agents | SCHERING CORPORATION (US) | 1990-03-06 | — | — | US | disclosed |
| US-4840772-A | KIT WITH CONTAINERS OF AGENT TO REDUCE INTRAOCULAR PRESSURE AND ANTIINFLAMMATORY STEROID OR BETA-BLOCKER | SCHERING CORPORATION (US) | 1989-06-20 | — | — | US | disclosed |
| US-4783444-A | SUBSTITUTED DIPEPTIDES | SCHERING CORPORATION (US) | 1988-11-08 | — | — | US | disclosed |
| US-4778795-A | Carboxyalkyl dipeptides as antiglaucoma agents | SCHERING CORPORATION (US) | 1988-10-18 | — | — | US | disclosed |
| EP-0236307-A1 | ANTIHYPERTENSIVE AGENTS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESSES FOR THE PREPARATION OF THE AGENTS AND COMPOSITIONS. | SCHERING CORP (US) | 1987-09-16 | — | — | EP | disclosed |
| US-4691049-A | Process for preparing a specific diastereomer of a monoamino dicarboxylic acid ester | SCHERING CORPORATION (US) | 1987-09-01 | — | — | US | disclosed |
| WO-1987001707-A1 | ANTIHYPERTENSIVE AGENTS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESSES FOR THE PREPARATION OF THE AGENTS AND COMPOSITIONS | SCHERING CORPORATION (US) | 1987-03-26 | — | — | WO | disclosed |
| US-4616012-A | BENZOTHIADIZINYL AND QUINAZOLINYL DERIVATIVES | SCHERING CORPORATION (US) | 1986-10-07 | — | — | US | disclosed |
| US-4584285-A | Antihypertensive agents | SCHERING CORPORATION (US) | 1986-04-22 | — | — | US | disclosed |
| US-4559340-A | DIURETICS; GLAUCOMA | SCHERING CORPORATION (US) | 1985-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255101-A1 | NITRIC OXIDE DONATING DIURETIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NOS1, NOS3, NOS2 | TDP1 2841/4885ALDH1A1 954/4885CYP1A2 703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.